A detailed history of Northern Trust Corp transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 433,642 shares of TRVI stock, worth $1.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
433,642
Previous 321,102 35.05%
Holding current value
$1.84 Million
Previous $956,000 51.46%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.58 - $3.51 $290,353 - $395,015
112,540 Added 35.05%
433,642 $1.45 Million
Q2 2024

Aug 14, 2024

SELL
$2.44 - $3.36 $16,079 - $22,142
-6,590 Reduced 2.01%
321,102 $956,000
Q1 2024

May 14, 2024

BUY
$1.3 - $3.7 $17,568 - $50,001
13,514 Added 4.3%
327,692 $1.13 Million
Q4 2023

Feb 13, 2024

SELL
$1.06 - $2.05 $1,460 - $2,824
-1,378 Reduced 0.44%
314,178 $420,000
Q3 2023

Nov 13, 2023

SELL
$2.11 - $2.47 $12,662 - $14,822
-6,001 Reduced 1.87%
315,556 $687,000
Q2 2023

Aug 11, 2023

BUY
$1.8 - $3.44 $463,273 - $885,366
257,374 Added 401.0%
321,557 $768,000
Q1 2023

May 15, 2023

BUY
$1.69 - $2.97 $17,014 - $29,901
10,068 Added 18.6%
64,183 $118,000
Q4 2022

Feb 13, 2023

BUY
$1.61 - $2.42 $22,842 - $34,334
14,188 Added 35.53%
54,115 $104,000
Q3 2022

Nov 14, 2022

SELL
$1.54 - $4.28 $9,811 - $27,267
-6,371 Reduced 13.76%
39,927 $61,000
Q2 2022

Aug 12, 2022

BUY
$1.8 - $3.39 $62,791 - $118,256
34,884 Added 305.62%
46,298 $130,000
Q3 2020

Nov 16, 2020

SELL
$3.5 - $7.62 $16,058 - $34,960
-4,588 Reduced 28.67%
11,414 $46,000
Q2 2020

Aug 14, 2020

SELL
$2.51 - $6.87 $1,199 - $3,283
-478 Reduced 2.9%
16,002 $105,000
Q2 2019

Aug 13, 2019

BUY
$7.5 - $10.12 $123,600 - $166,777
16,480 New
16,480 $124,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $247M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.